Compare Macy's Inc (M) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Tempus AI — how do they compare? Macy's Inc trades at $22.79 (market cap $5.95B), while Tempus AI trades at $70.19 (market cap $12.77B). The key difference: Tempus AI is far larger — about 2.1× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Tempus AI for 22 Days on average.
| M | TEM | |
|---|---|---|
Market Cap | $5.95B | $12.77B |
Volume | 11,329,747 | 8,980,490 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $26.21 | $99.28 |
52-Week Low | $16.51 | $41.55 |
Typical Hold Time | 58 Days | 22 Days |
Enterprise Value | $9.75B | $13.40B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.79, up 1.47% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals, with Q2 2026 EPS beating estimates and a raised 2026 outlook. Valuation remains attractive with a P/E of 8.35 and P/S of 0.27, while cash flow trends have strengthened, with net cash flow turning positive in 2024 and 2025. Recent news highlights progress in the 'Bold New Chapter' strategy, focusing on digital and omnichannel growth.
The outlook for Macy's is cautiously optimistic, supported by cheap valuations and strategic initiatives, but risks include competitive pressures and uneven earnings growth. Analyst consensus is mixed with a $24.25 price target, indicating modest upside potential. Key investment opportunities lie in dividend yield and turnaround execution, while risks involve margin pressure and macroeconomic headwinds affecting retail demand.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
